Countdown to 2021 CBIIC:

TAN Lingshi

Chairman & CEO of dMed Biopharmaceutical Co., Ltd.

Dr. Lingshi Tan received his PhD in Biostatistics from the University of Pittsburgh,is Chairman and CEO of dMed Biopharmaceutical Co., Ltd. dMed is a China based clinical CRO that provides comprehensive services to biopharmaceutical and medical device companies in China and globally, including advising customers on clinical development plan and regulatory strategy, as well as providing full support on clinical trial design and execution.


Prior to founding dMed, Dr. Tan was Pfizer’s Vice President of Worldwide Development Operations, Chairman and General Manager of Pfizer (China) Research & Development Co., Ltd (CRDC). After 9 years at Headquarters in New York, he was assigned to Shanghai to establish the CRDC in 2005. Under his leadership, the CRDC(Shanghai, Wuhan, Beijing) grew to an organization of more than 1,000 professionals and became an integral part of Pfizer’s global R&D network, focusing on Clinical Development, Safety, Regulatory, and Medical functions.


Dr. Tan is currently on the Board of Directors of DIA and the inaugural Chair of Innovation R&D Service Committee of PhIRDA. He also served as the inaugural Chair of R&D Committee of RDPAC.